Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy

BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirose, Chiemi, Fujii, Hironori, Iihara, Hirotoshi, Ishihara, Masashi, Nawa-Nishigaki, Minako, Kato-Hayashi, Hiroko, Ohata, Koichi, Sekiya, Kumiko, Kitahora, Mika, Matsuhashi, Nobuhisa, Takahashi, Takao, Okuda, Kumiko, Naruse, Masayo, Ishihara, Takuma, Sugiyama, Tadashi, Yoshida, Kazuhiro, Suzuki, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686000/
https://www.ncbi.nlm.nih.gov/pubmed/32281034
http://dx.doi.org/10.1007/s00520-020-05443-8
_version_ 1783613277570334720
author Hirose, Chiemi
Fujii, Hironori
Iihara, Hirotoshi
Ishihara, Masashi
Nawa-Nishigaki, Minako
Kato-Hayashi, Hiroko
Ohata, Koichi
Sekiya, Kumiko
Kitahora, Mika
Matsuhashi, Nobuhisa
Takahashi, Takao
Okuda, Kumiko
Naruse, Masayo
Ishihara, Takuma
Sugiyama, Tadashi
Yoshida, Kazuhiro
Suzuki, Akio
author_facet Hirose, Chiemi
Fujii, Hironori
Iihara, Hirotoshi
Ishihara, Masashi
Nawa-Nishigaki, Minako
Kato-Hayashi, Hiroko
Ohata, Koichi
Sekiya, Kumiko
Kitahora, Mika
Matsuhashi, Nobuhisa
Takahashi, Takao
Okuda, Kumiko
Naruse, Masayo
Ishihara, Takuma
Sugiyama, Tadashi
Yoshida, Kazuhiro
Suzuki, Akio
author_sort Hirose, Chiemi
collection PubMed
description BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the relationship between outpatient chemotherapy–induced adverse events and QOL. METHODS: A single-center retrospective descriptive study was conducted in patients who received outpatient chemotherapy at Gifu University Hospital (Gifu, Japan) between September 2017 and December 2018. The utility values of QOL, type and severity of adverse events, type of cancer, chemotherapy regimen, and other patient demographics were analyzed. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. QOL was evaluated using the Japanese version of the EuroQol 5 Dimension 5 Level (EQ-5D-5L). Associations between the EQ-5D-5L utility value and serious adverse events were assessed using adjusted (age and sex) odds ratios obtained with a proportional odds logistic regression model. RESULTS: Data from 1008 patients who received 4695 chemotherapy cycles were analyzed. According to proportional odds logistic regression, the adverse events that significantly correlated with a decreased EQ-5D-5L utility value were malaise, edema of the limbs, peripheral neuropathy, pruritus, and dry skin. Based on the proportional odds logistic analysis, neither cancer type nor anticancer drugs were significantly correlated with the EQ-5D-5L utility value in patients who received chemotherapy. Pharmaceutical care for peripheral neuropathy significantly improved patients’ EQ-5D-5L utility value from 0.747 to 0.776 (P < 0.01). CONCLUSIONS: Adverse events (i.e., peripheral neuropathy, malaise, and edema of the limbs) are significantly correlated with a decrease in QOL, regardless of the type of cancer or anticancer drugs used. Pharmaceutical care provided by pharmacists in collaboration with physicians may improve QOL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-020-05443-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7686000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76860002020-11-30 Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy Hirose, Chiemi Fujii, Hironori Iihara, Hirotoshi Ishihara, Masashi Nawa-Nishigaki, Minako Kato-Hayashi, Hiroko Ohata, Koichi Sekiya, Kumiko Kitahora, Mika Matsuhashi, Nobuhisa Takahashi, Takao Okuda, Kumiko Naruse, Masayo Ishihara, Takuma Sugiyama, Tadashi Yoshida, Kazuhiro Suzuki, Akio Support Care Cancer Original Article BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the relationship between outpatient chemotherapy–induced adverse events and QOL. METHODS: A single-center retrospective descriptive study was conducted in patients who received outpatient chemotherapy at Gifu University Hospital (Gifu, Japan) between September 2017 and December 2018. The utility values of QOL, type and severity of adverse events, type of cancer, chemotherapy regimen, and other patient demographics were analyzed. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. QOL was evaluated using the Japanese version of the EuroQol 5 Dimension 5 Level (EQ-5D-5L). Associations between the EQ-5D-5L utility value and serious adverse events were assessed using adjusted (age and sex) odds ratios obtained with a proportional odds logistic regression model. RESULTS: Data from 1008 patients who received 4695 chemotherapy cycles were analyzed. According to proportional odds logistic regression, the adverse events that significantly correlated with a decreased EQ-5D-5L utility value were malaise, edema of the limbs, peripheral neuropathy, pruritus, and dry skin. Based on the proportional odds logistic analysis, neither cancer type nor anticancer drugs were significantly correlated with the EQ-5D-5L utility value in patients who received chemotherapy. Pharmaceutical care for peripheral neuropathy significantly improved patients’ EQ-5D-5L utility value from 0.747 to 0.776 (P < 0.01). CONCLUSIONS: Adverse events (i.e., peripheral neuropathy, malaise, and edema of the limbs) are significantly correlated with a decrease in QOL, regardless of the type of cancer or anticancer drugs used. Pharmaceutical care provided by pharmacists in collaboration with physicians may improve QOL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-020-05443-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-12 2020 /pmc/articles/PMC7686000/ /pubmed/32281034 http://dx.doi.org/10.1007/s00520-020-05443-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Hirose, Chiemi
Fujii, Hironori
Iihara, Hirotoshi
Ishihara, Masashi
Nawa-Nishigaki, Minako
Kato-Hayashi, Hiroko
Ohata, Koichi
Sekiya, Kumiko
Kitahora, Mika
Matsuhashi, Nobuhisa
Takahashi, Takao
Okuda, Kumiko
Naruse, Masayo
Ishihara, Takuma
Sugiyama, Tadashi
Yoshida, Kazuhiro
Suzuki, Akio
Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title_full Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title_fullStr Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title_full_unstemmed Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title_short Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
title_sort real-world data of the association between quality of life using the euroqol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686000/
https://www.ncbi.nlm.nih.gov/pubmed/32281034
http://dx.doi.org/10.1007/s00520-020-05443-8
work_keys_str_mv AT hirosechiemi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT fujiihironori realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT iiharahirotoshi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT ishiharamasashi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT nawanishigakiminako realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT katohayashihiroko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT ohatakoichi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT sekiyakumiko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT kitahoramika realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT matsuhashinobuhisa realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT takahashitakao realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT okudakumiko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT narusemasayo realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT ishiharatakuma realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT sugiyamatadashi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT yoshidakazuhiro realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy
AT suzukiakio realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy